Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention ...

Mark S. King’s January 10 blog post on his award-winning "My Fabulous Disease" site made me aware of a new, and troubling, ...

Gilead is mounting a challenge against GlaxoSmithKline’s HIV drug, Tivicay, with its rival integrase inhibitor bictegravir. At the same time, GSK’s ViiV HIV unit hit back with data of its own ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lyell Immunopharma (LYEL – Research Report) ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory ...